Publications by authors named "K Torimoto"

Gilteritinib is a tyrosine kinase inhibitor (TKI) that treats acute myeloid leukemia (AML) by inhibiting FMS-like tyrosine kinase 3 (FLT3). This is a report on hypopituitarism induced by gilteritinib and its resolution following withdrawal. A 54-year-old woman was treated with gilteritinib for AML.

View Article and Find Full Text PDF
Article Synopsis
  • This study evaluated health-related quality of life (HRQoL) in 42 patients with advanced urothelial carcinoma (aUC) receiving various immune checkpoint inhibitors (ICIs), including pembrolizumab, avelumab, and nivolumab.
  • Results showed significant improvements in HRQoL for patients on pembrolizumab, while those on avelumab and nivolumab experienced mostly stable or deteriorated HRQoL, particularly in social and general health aspects.
  • The findings suggest that despite the challenges, many patients on ICI therapy maintained a stable HRQoL, aligning with previous clinical trial evidence.
View Article and Find Full Text PDF

Background: Controversial issues in registering candidates for deceased-donor kidney transplantation (DDKT) comprise various factors, including age, life expectancy, and dialysis duration. We investigated patient characteristics on the waiting list and discussed suitable criteria in Japan, which has a long waiting period.

Methods: This study included 592 patients on the waiting list for DDKT at our institute between 1982 and 2023.

View Article and Find Full Text PDF

Unresectable, metastatic, advanced urothelial carcinoma (aUC) is an aggressive disease and is treated with platinum-containing first-line chemotherapy, followed by immune checkpoint inhibitors and antibody-drug conjugates. Response to first-line chemotherapy is a vital priority in sequential treatment strategies because a better response to first-line chemotherapy is associated with a better response to subsequent therapies. Gemcitabine plus carboplatin chemotherapy is conventionally recommended for cisplatin-ineligible patients.

View Article and Find Full Text PDF

Background: Photodynamic diagnosis-assisted transurethral resection of bladder tumors (PDD-TURBT) enhances detection of elusive lesions compared to standard white light-transurethral resection of bladder tumors (WL-TURBT). If minimal light exposure during PDD-TURBT induces the accumulation of reactive oxygen species (ROS), potentially resulting in phototoxicity in small lesions, apoptosis may be triggered in residual small tumors, allowing them to escape resection. We investigated the hypothesis of a potential photodynamic therapeutic effect during PDD-TURBT.

View Article and Find Full Text PDF